ETS Translocation Variant 5 (ETV5) Antibody

The ETS family of transcription factors, characterized by an evolutionarily conserved DNA-binding domain, regulates expression of more than 300 target genes by binding to a purine-rich GGAA/T core sequence. Depending on the cellular context, they can function as transactivators or transrepressors. Ets proteins have been implicated in regulation of gene expression during a variety of biological processes, including growth control, transformation, T-cell activation, and developmental programs in many organisms. Signals regulating cell growth are transmitted from outside the cell to the nucleus by growth factors and their receptors, G-proteins, kinases and transcription factors. It was shown that ETS signal transduction is implicated in hematopoiesis and angiogenesis at the earliest stages of embryogenesis, and is later involved in tissue development. Deregulated expression and/or formation of chimeric fusion proteins of the ETS family due to proviral insertion or chromosome translocation is associated with leukemias and with specific types of solid tumors.1 Among the multiple Ets proteins, the PEA3 group consists of ETV1 (Ets variant gene 1; also called ER81), ETV4 (also called PEA3) and ETV5 (also called ERM). All three members are 95% identical in the ETS domain and more than 85% in the acidic transactivation domain. Several studies suggest that the PEA3 group proteins are involved in intestinal tumors, gastric cancer, and breast cancer metastasis. In nearly all Ewing?s sarcoma tumors, EWS, which encodes a RNA-binding protein, is fused by chromosomal translocation to an Ets gene, including FLI, ERG, ETV4, and ETV1. This results in the expression of chimeric proteins that may be important in tumor cell transformation.2 Recently, it was reported that TMPRSS2, an AR-regulated gene, is fused by translocation to the ETV1, ERG, or ETV4 gene in a subset of prostate cancers. These findings suggest an important role for PEA3 proteins in prostate cancer.3 In addition Ets family members have been correlated to tumor progression by upregulating the expression of matrix-degrading proteases. The acquisition of a migratory phenotype by the epithelial tumor cells together with the remodeling of the extracellular matrix must accompany the process of cancer cell invasion. Indeed, ETV5 has been shown to act through matrix metalloproteinase-2 gelatinolytic activity to confer invasive capabilities, associated with an initial switch to myometrial infiltration.4.

Target	ETS Translocation Variant 5 (ETV5)
Clonality	Polyclonal
Reactivity	Human
Tested Applications	ELISA, WB, FCM
Host	Rabbit
Recommended dilutions	WB: 1/1000, FCM: 1/10 - 1/50. Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Immunogen	KLH-conjugated synthetic peptide between 8-36 amino acids from the N-terminal region of human ETV5.
Isotype	IgG
Form	Liquid
Purification	Purified through a protein A column, followed by peptide affinity purification.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC	P41161 (UniProt, ExPASy)
UniProt Secondary AC	A6NH46, B7Z7D7, Q6IBN5
UniProt Entry Name	ETV5_HUMAN
Gene Symbol	ETV5
NCBI Accession	NP_004445.1
KEGG	hsa:2119
String	9606.ENSP00000306894
Molecular Weight	Calculated MW: 57.8 kDa
Buffer	PBS containing 0.09% sodium azide.
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.

Research Articles on ETS Translocation Variant 5 (ETV5)

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue